德谷胰岛素利拉鲁肽注射液致过敏性荨麻疹2例

Two cases of allergic urticaria induced by insulin degludec and liraglutideinjection

2例女性糖尿病患者皮下注射德谷胰岛素利拉鲁肽注射液,分别于1 d和2 d后出现过敏性荨麻疹,停药换用其他胰岛素降糖治疗,同时给予地塞米松、西替利嗪、外用乳膏抗过敏,患者症状逐渐好转。2例不良反应与可疑药物德谷胰岛素利拉鲁肽注射液的关联性评价结果均为“很可能有关”。查阅国内外文献,使用德谷胰岛素利拉鲁肽注射液发生过敏性荨麻疹少有报道。本文通过分析2例不良反应的临床特点,探讨临床药师在判断过敏源和参与降糖方案调整中所起的作用,为临床个体化用药与安全用药提供参考。

Two female patients received insulin degludec and liraglutide injection and developed allergic urticaria after 1 day and 2 days respectively.The drug was discontinued and other insulin was used for glucose-lowering therapy,and anti-allergy treatment was administered with dexamethasone,cetirizine and topical cream,then two patients'symptoms gradually improved.The results of the association between the two adverse drug reactions and insulin degludec and liraglutide injection were"probably relevant".According to the domestic and foreign literature,there were rare reports of allergic urticaria in diabetic patients using insulin degludec and liraglutide injection.By analyzing the clinical characteristics of the two cases of adverse drug reactions,the role of clinical pharmacists in judging allergens and participating in the adjustment of hypoglycemic regimens is explored,which provides reference for individualized clinical medication and safe medication.